Standard Chemical & Pharmaceutical Co. Ltd. AI Stock Analysis
Want to see TW:1720 full AI Analyst Report?
Standard Chemical & Pharmaceutical Co. Ltd. (1720) AI Stock Analysis
Standard Chemical & Pharmaceutical Co. Ltd.
(TWSE:1720)
The company's financial foundation is a significant strength, characterized by a debt-light balance sheet and superb free cash flow generation. However, this is offset by weak technical momentum, with the stock trading below key moving averages and showing bearish signals. The low P/E ratio and solid dividend yield provide a valuation cushion, making the stock fundamentally attractive but currently out of favor in the market.
Standard Chemical & Pharmaceutical Co. Ltd. (1720) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 10.91B
- Dividend Yield
- 3.62%
- Average Volume (3M)
- 224.76K
- Price to Earnings (P/E)
- 10.8
- Beta (1Y)
- 0.11
- Revenue Growth
- 4.62%
- EPS Growth
- 9.56%
- Country
- TW
- Employees
- 1,130
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Standard Chemical & Pharmaceutical Co. Ltd. Business Overview & Revenue Model
Company Description
Standard Chem & Pharm Co. Ltd. (SCP) is a Taiwanese enterprise specializing in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products, nutritional supplements, and Active Pharmaceutical Ingredients (APIs)...
Standard Chemical & Pharmaceutical Co. Ltd. Financial Statement Overview
Summary
Strong financial health driven by excellent cash flow (Score 85) and a robust, deleveraging balance sheet (Score 78). Modest but stable revenue growth and improving profitability support a solid, though not exceptional, overall financial profile.
Income Statement
72PositiveBalance Sheet
78PositiveCash Flow
85Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.23B | 7.02B | 6.79B | 6.24B | 5.85B | 4.60B |
| Gross Profit | 3.13B | 2.91B | 2.99B | 2.73B | 2.49B | 2.07B |
| EBITDA | 1.91B | 1.80B | 2.06B | 1.61B | 1.66B | 1.25B |
| Net Income | 1.00B | 927.66M | 880.50M | 834.89M | 1.15B | 706.73M |
Balance Sheet | ||||||
| Total Assets | 12.12B | 11.80B | 11.18B | 11.19B | 10.97B | 10.10B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16B | 2.39B | 1.81B | 2.28B | 2.60B | 2.99B |
| Total Debt | 970.30M | 1.13B | 921.19M | 1.33B | 2.25B | 1.97B |
| Total Liabilities | 2.44B | 2.51B | 2.20B | 3.05B | 3.53B | 3.30B |
| Stockholders Equity | 6.45B | 6.12B | 5.91B | 5.30B | 4.75B | 4.34B |
Cash Flow | ||||||
| Free Cash Flow | 1.23B | 1.38B | 1.10B | 710.83M | 30.29M | 609.12M |
| Operating Cash Flow | 1.72B | 1.87B | 1.69B | 1.34B | 1.23B | 827.03M |
| Investing Cash Flow | -822.93M | -1.31B | -771.69M | -485.50M | -1.08B | 819.12M |
| Financing Cash Flow | -722.30M | -309.71M | -1.44B | -1.08B | -465.44M | -117.54M |
Standard Chemical & Pharmaceutical Co. Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:1720, the sentiment is Negative. The current price of 55.30 is below the 20-day moving average (MA) of 56.02, below the 50-day MA of 56.24, and below the 200-day MA of 55.59, indicating a bearish trend. The MACD of -0.40 indicates Positive momentum. The RSI at 41.59 is Neutral, neither overbought nor oversold. The STOCH value of 40.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TW:1720.
Standard Chemical & Pharmaceutical Co. Ltd. Peers Comparison
Overall Rating
TW:321873Outperform
TW:172065Neutral
TW:653552Neutral
TW:657642Neutral
TW:694540Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | TWD 10.42B | 9.71 | ― | 6.33% | 4.80% | 8.73% | |
| 65Neutral | TWD 10.87B | 10.84 | ― | 3.62% | 4.62% | 9.56% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | TWD 14.66B | -33.97 | ― | ― | -24.84% | 9.09% | |
| 42Neutral | TWD 11.01B | -1165.00 | ― | ― | 6.41% | ― | |
| 40Underperform | TWD 11.70B | -34.27 | ― | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1720 | Standard Chemical & Pharmaceutical Co. Ltd. | 55.30 | -0.17 | -0.30% | |
| TW:3218 | Universal Vision Biotechnology Co., Ltd. | 122.50 | -18.16 | -12.91% | |
| TW:6467 | TAHO Pharmaceuticals Ltd | 224.50 | 52.00 | 30.14% | |
| TW:6535 | LUMOSA THERAPEUTICS CO LTD | 83.30 | -98.70 | -54.23% | |
| TW:6576 | Foresee Pharmaceuticals Co., Ltd. | 69.90 | -5.90 | -7.78% | |
| TW:6945 | AP Biosciences, Inc. | 120.00 | 11.50 | 10.60% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
